Is it possible to support the biopharmaceutical process scale-up with science-based methodologies even when a limited number of experiments can be performed and few data are available?
Our new contribution (https://www.mdpi.com/2227-9717/10/9/1796) proposes the use of digital models to perform data augmentation through in-silico experimentation.